Skip to main content
Top
Published in: Clinical and Experimental Nephrology 6/2011

01-12-2011 | Case Report

Renal complications of Castleman’s disease: report of two cases and analysis of 75 cases

Authors: Xiang-Gui Yuan, Wen Hu, Fei-Fei Chen, Bin-Feng Huang, Xiao-Ying Zhao

Published in: Clinical and Experimental Nephrology | Issue 6/2011

Login to get access

Abstract

Biopsy-proven renal complications of Castleman’s disease (CD) are rare and current knowledge is largely based on sporadic case reports. We reported two more cases, both of which were multicentric CD with hyaline-vascular pathological pattern and presented with chronic renal failure. Case 1 was multicentric CD with renal mesangial proliferative glomerulonephritis complications, and case 2 was multicentric CD with membranoproliferative glomerulonephritis-like complications. Although both were eventually administered corticosteroids combined with cytotoxic drugs, both behaved in an aggressive and relapsing manner. We then made an analysis of 75 cases of biopsy-proven renal complications of CD (including our two cases) which were reported in 51 English literatures from January 1954 to March 2011. We found that the clinical and histological findings of renal complications of CD were heterogeneous. Death was observed in 17% patients after a median follow-up time of 22 months (0–204 months) since histological diagnosis of renal complications. The estimated 5-year cumulative survival rate was 75%. Better understanding and therapeutic interventions are required in further investigations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16:236–46.PubMedCrossRef Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009;16:236–46.PubMedCrossRef
2.
go back to reference El Karoui K, Vuiblet V, Dion D, Izzedine H, Guitard J, Frimat L, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant. 2011;26:599–609.PubMedCrossRef El Karoui K, Vuiblet V, Dion D, Izzedine H, Guitard J, Frimat L, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant. 2011;26:599–609.PubMedCrossRef
3.
go back to reference Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.PubMedCrossRef Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–86.PubMedCrossRef
4.
go back to reference Seida A, Wada J, Morita Y, Baba M, Eguchi J, Nishimoto N, et al. Multicentric Castleman’s disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis. 2004;43:E3–9.PubMedCrossRef Seida A, Wada J, Morita Y, Baba M, Eguchi J, Nishimoto N, et al. Multicentric Castleman’s disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury? Am J Kidney Dis. 2004;43:E3–9.PubMedCrossRef
5.
go back to reference Kazes I, Deray G, Jacobs C. Castleman disease and renal amyloidosis. Ann Intern Med. 1995;122:395–6.PubMed Kazes I, Deray G, Jacobs C. Castleman disease and renal amyloidosis. Ann Intern Med. 1995;122:395–6.PubMed
6.
go back to reference Humpherys SR, Holley KE, Smith LH, McIlrath DC. Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with nephrotic syndrome. Mayo Clin Proc. 1975;50:317–21.PubMed Humpherys SR, Holley KE, Smith LH, McIlrath DC. Mesenteric angiofollicular lymph node hyperplasia (lymphoid hamartoma) with nephrotic syndrome. Mayo Clin Proc. 1975;50:317–21.PubMed
7.
go back to reference Ruggieri G, Barsotti P, Coppola G, Spinelli C, Balducci A, Ventola FR, et al. Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies. Am J Nephrol. 1990;10:323–8.PubMedCrossRef Ruggieri G, Barsotti P, Coppola G, Spinelli C, Balducci A, Ventola FR, et al. Membranous nephropathy associated with giant lymph node hyperplasia. A case report with histological and ultrastructural studies. Am J Nephrol. 1990;10:323–8.PubMedCrossRef
8.
go back to reference Perfetti V, Bellotti V, Maggi A, Arbustini E, De Benedetti F, Paulli M, et al. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman’s disease. Am J Hematol. 1994;46:189–93.PubMedCrossRef Perfetti V, Bellotti V, Maggi A, Arbustini E, De Benedetti F, Paulli M, et al. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman’s disease. Am J Hematol. 1994;46:189–93.PubMedCrossRef
9.
go back to reference Sugimoto T, Ito J, Takeda N, Gasyu I, Okazaki T, Sakaguchi M, et al. A case of Castleman’s disease complicated with nephrotic syndrome due to glomerulopathy mimicking membranoproliferative glomerulonephritis. Am J Med Sci. 2008;335:495–8.PubMedCrossRef Sugimoto T, Ito J, Takeda N, Gasyu I, Okazaki T, Sakaguchi M, et al. A case of Castleman’s disease complicated with nephrotic syndrome due to glomerulopathy mimicking membranoproliferative glomerulonephritis. Am J Med Sci. 2008;335:495–8.PubMedCrossRef
10.
go back to reference Paydas S, Gonlusen G, Sagliker Y. Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman’s disease. Nephron. 1995;71:463–4.PubMedCrossRef Paydas S, Gonlusen G, Sagliker Y. Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman’s disease. Nephron. 1995;71:463–4.PubMedCrossRef
11.
go back to reference Menegato MA, Canelles MF, Tonutti E, Pizzolitto S. Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman’s disease. Clin Nephrol. 2004;61:352–6.PubMed Menegato MA, Canelles MF, Tonutti E, Pizzolitto S. Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman’s disease. Clin Nephrol. 2004;61:352–6.PubMed
12.
go back to reference Suneja S, Chidambaram M, Herzenberg AM, Bargman JM. Kidney involvement in multicentric Castleman disease. Am J Kidney Dis. 2009;53:550–4.PubMedCrossRef Suneja S, Chidambaram M, Herzenberg AM, Bargman JM. Kidney involvement in multicentric Castleman disease. Am J Kidney Dis. 2009;53:550–4.PubMedCrossRef
13.
go back to reference Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.PubMed
14.
go back to reference Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20:2055–64.PubMedCrossRef Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20:2055–64.PubMedCrossRef
15.
go back to reference Ogita M, Hoshino J, Sogawa Y, Sawa N, Katori H, Takemoto F, et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol. 2007;68:171–6.PubMed Ogita M, Hoshino J, Sogawa Y, Sawa N, Katori H, Takemoto F, et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol. 2007;68:171–6.PubMed
16.
go back to reference Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.PubMed Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.PubMed
Metadata
Title
Renal complications of Castleman’s disease: report of two cases and analysis of 75 cases
Authors
Xiang-Gui Yuan
Wen Hu
Fei-Fei Chen
Bin-Feng Huang
Xiao-Ying Zhao
Publication date
01-12-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 6/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0499-9

Other articles of this Issue 6/2011

Clinical and Experimental Nephrology 6/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.